Transitional Cell Carcinoma
- June 17, 2018
- by BluePearl Science Team
BluePearl pet hospitals in Overland Park and Southfield are participating in a fully-funded study evaluating the safety and preliminary pain management and potential anti-cancer effect of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).
NOTE: Anti-cancer therapies must be discontinued 21 days prior to enrollment. Medications targeted at the treatment of TCC-associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study.
For eligibility, dogs must meet the criteria below.
Kansas – Overland Park Participation Contact Dr. Heather Heeb, Adrienne Hagar, or Beth Rogers at (913) 642-9563.
Michigan – Southfield Participation Contact Dr. Angela Kozicki or Ashley Davis at (248) 354-6640.
Utah – Midvale Participation Contact Dr. Katherine Wright or Ashley Harmon-Neilson at (801) 871-0600.